Two-year study will help experts understand why certain diseases affect some people more than others and why they progress differently in different people
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 44th Annual Global Healthcare Conference on. | June 5, 2023
Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc and Moderna Inc in Delaware federal court, again claiming that the companies COVID-19 vaccines infringe. | May 26, 2023
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report. This year’s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity.